TuHURA Biosciences Secures $3 Million Bridge Loan from Matthew Nachtrab Revocable Trust

Reuters

2025/11/01

<a href="https://laohu8.com/S/HURA">TuHURA Biosciences</a> Secures $3 Million Bridge Loan from Matthew Nachtrab Revocable Trust

Tuhura Biosciences Inc. has entered into a new secured bridge loan agreement with the Matthew Nachtrab Revocable Trust, dated October 27, 2025. Under the terms of the agreement, the lender will provide up to $3 million in loans, with an initial advance of $1.5 million. The company may access the remaining funds during a 30-day availability period. The loans bear interest at 3% per month, with all principal and accrued interest due by December 31, 2025, or 30 days after a qualifying equity financing over $12 million. The agreement is secured by a first priority security interest in Tuhura's U.S. patents related to its ImmuneFx technology. In connection with each loan advance, Tuhura will issue warrants to the lender to purchase common stock. Proceeds will be used for working capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-260924), on October 31, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2580141944"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580141944\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580141944?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-01 05:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580141944","market":"fut","top_or_hot":-1,"title":"TuHURA Biosciences Secures $3 Million Bridge Loan from Matthew Nachtrab Revocable Trust","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/HURA\">TuHURA Biosciences</a> Secures $3 Million Bridge Loan from Matthew Nachtrab Revocable Trust\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tuhura Biosciences Inc. has entered into a new secured bridge loan agreement with the Matthew Nachtrab Revocable Trust, dated October 27, 2025. Under the terms of the agreement, the lender will provide up to $3 million in loans, with an initial advance of $1.5 million. The company may access the remaining funds during a 30-day availability period. The loans bear interest at 3% per month, with all principal and accrued interest due by December 31, 2025, or 30 days after a qualifying equity financing over $12 million. The agreement is secured by a first priority security interest in Tuhura's U.S. patents related to its ImmuneFx technology. In connection with each loan advance, Tuhura will issue warrants to the lender to purchase common stock. Proceeds will be used for working capital.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-260924), on October 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TuHURA Biosciences Secures $3 Million Bridge Loan from Matthew Nachtrab Revocable Trust</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTuHURA Biosciences Secures $3 Million Bridge Loan from Matthew Nachtrab Revocable Trust\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-01 05:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/HURA\">TuHURA Biosciences</a> Secures $3 Million Bridge Loan from Matthew Nachtrab Revocable Trust\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tuhura Biosciences Inc. has entered into a new secured bridge loan agreement with the Matthew Nachtrab Revocable Trust, dated October 27, 2025. Under the terms of the agreement, the lender will provide up to $3 million in loans, with an initial advance of $1.5 million. The company may access the remaining funds during a 30-day availability period. The loans bear interest at 3% per month, with all principal and accrued interest due by December 31, 2025, or 30 days after a qualifying equity financing over $12 million. The agreement is secured by a first priority security interest in Tuhura's U.S. patents related to its ImmuneFx technology. In connection with each loan advance, Tuhura will issue warrants to the lender to purchase common stock. Proceeds will be used for working capital.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-260924), on October 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HURA","symbol_name":"TuHURA Biosciences, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL8VqVb3:1","article_id":"2580141944","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580141944","pubTimestamp":1761944478,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tuhura Biosciences Inc. has entered into a new secured bridge loan agreement with the Matthew Nachtrab Revocable Trust, dated October 27, 2025. Under the terms of the agreement, the lender will provide up to $3 million in loans, with an initial advance of $1.5 million. The company may access the remaining funds during a 30-day availability period. The loans bear interest at 3% per month, with all principal and accrued interest due by December 31, 2025, or 30 days after a qualifying equity financing over $12 million. The agreement is secured by a first priority security interest in Tuhura's U.S. patents related to its ImmuneFx technology. In connection with each loan advance, Tuhura will issue warrants to the lender to purchase common stock. Proceeds will be used for working capital.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HURA":"TuHURA Biosciences, Inc.","BK4139":"生物科技"},"translate_title":"TuHURA Biosciences从Matthew Nachtrab可撤销信托获得300万美元过桥贷款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HURA":0.9},"content_text":"TuHURA Biosciences Secures $3 Million Bridge Loan from Matthew Nachtrab Revocable Trust\n    \n\n        Tuhura Biosciences Inc. has entered into a new secured bridge loan agreement with the Matthew Nachtrab Revocable Trust, dated October 27, 2025. Under the terms of the agreement, the lender will provide up to $3 million in loans, with an initial advance of $1.5 million. The company may access the remaining funds during a 30-day availability period. The loans bear interest at 3% per month, with all principal and accrued interest due by December 31, 2025, or 30 days after a qualifying equity financing over $12 million. The agreement is secured by a first priority security interest in Tuhura's U.S. patents related to its ImmuneFx technology. In connection with each loan advance, Tuhura will issue warrants to the lender to purchase common stock. Proceeds will be used for working capital.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-260924), on October 31, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}